Correlation Between Hepatic Fibrosis and Cardiovascular Risk Evaluated by Non-invasive Tests in Patients With NAFLD
NCT ID: NCT04774302
Last Updated: 2025-06-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
292 participants
OBSERVATIONAL
2021-03-18
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-invasive Evaluation of Hepatic Fibrosis in Patients With the Metabolic Syndrome
NCT00399932
NASH and Coronary Disease
NCT03819283
Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes
NCT06456970
Fatty Liver and Ectopic Fat in Overweight and Obese Patients
NCT00886301
Comparison of Two sTRAtegies For the Non-Invasive Diagnosis of advanCed Liver Fibrosis in NAFLD
NCT04681573
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient without known heart disease
* Patient agreeing to participate and who has given his non opposition
Exclusion Criteria
* Already known coronary artery disease
* Pregnancy or breastfeeding in progress
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinique Pasteur
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Maeva GUILLAUME
Principal investigator, MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maeva GUILLAUME, MD
Role: PRINCIPAL_INVESTIGATOR
Clinique Pasteur
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinique Pasteur
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A03423-36
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.